Published in Drug Week, April 23rd, 2004
The study was designed to evaluate enoximone capsules as effective treatment to wean patients off of IV inotrope therapy and potentially support the two ongoing phase III pivotal studies, ESSENTIAL I & II.
Analysis of the primary endpoint, wean success at 30 days, demonstrated a wean success rate of 61% in the enoximone-treated group and 51% in the placebo-treated group. This difference did not reach statistical...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.